Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance
Fractyl Health is concentrating resources on Revita after positive REMAIN-1 pivotal results, with the six-month co-primary endpoint met at p=0.0023 versus sham in post-GLP-1 weight regain. The company will cut roughly 45% of its workforce, halving quarterly cash burn to about $8 million by end of Q2 2027 and extending its cash runway into Q2 2027. Rejuva gene therapy development is discontinued and the company is exploring strategic alternatives, while co-founder Jay Caplan retires effective October 30, 2026. Revita's planned FDA De Novo submission is targeted for late Q4 2026, with 12-month pivotal data in Q1 2027, potential authorization in late 2027, and a potential U.S.
Key figures
- Drug Name
- Revita (Revita DMR System)
- Phase Of Trial
- Pivotal (REMAIN-1)
- Cash runway
- into Q2 2027
- Remain 1 pvalue
- p=0.0023
- Potential launch
- early 2028
- Twelve month data
- Q1 2027
- De novo submission
- late Q4 2026
- Workforce reduction
- 45%
- Potential authorization
- late 2027
- Quarterly cash burn target
- $8 million
- Quarterly cash burn reduction
- ~50%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.